Business
CollPlant CEO Yehiel Tal to Discuss Emerging Uses of rhCollagen in Aesthetic and Regenerative Medicine at NANO.IL.2021 Conference
REHOVOT, Israel, Sept. 27, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies
About this update from Collplant Biotechnologies Ltd.
[{"type":"text","content":"REHOVOT, Israel, Sept. 27, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced that Mr. Yehiel Tal, the Company's CEO, will present at The International Nanotechnology Conference to be held in Jerusalem, Israel, on October 6, 2021 at 4:55 - 5:15 p.m. IL time.\n\n \n \n \n \n \n \n\n \nIn his presentation, \"rhCollagen- the ideal nano building block in Regenerative Medicine,\" Mr. Tal will provide an overview of CollPlant's rhCollagen technology platform and its proprietary capabilities for tissue regeneration and organ manufacturing. He will also highlight the company's growth strategy and product pipeline including dermal fillers, BioInks, regenerative tissues matrixes, injectable and 3D bioprinted breast implants.\nThe conference will bring together International and Israeli experts from academia, business and government, to share knowledge of cutting-edge innovations and technologies, leading scientific achievements and unique business and investment opportunities in the nano-scale. \nAbout CollPlant\nCollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. The Company's products are based on its recombinant human collagen produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine. \nCollPlant recently entered a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market. Later in 2021, CollPlant entered a strategic co-development agreement with 3D Systems for a 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures in combination with an implant.\nFor more information, visit http://www.collplant.com.\nSafe Harbor Statements\nThis press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant's objectives plans and strategies, as well as statements, other than historical fac...